abapentin is an anticonvulsant drug used for the treatment of refractory partial seizures and is also widely used in the treatment of chronic neuropathic pain. Despite chemical similarity to the inhibitory neurotransmitter γ-aminobutyric acid (GABA) and despite the effort to increase lipophilicity of this GABA-mimetic agent, gabapentin neither mimics GABA nor acts specifically at GABA receptors or GABA synapses. 1, 2 Current evidence suggests that the most probable mechanism for the functional activity of gabapentinoid drugs in the treatment of epilepsy and neuropathic pain is their binding to the auxiliary α 2 δ subunit of voltage-dependent calcium channels (VDCCs) and subsequent functional modulation of these channels.
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2,3 α 2 δ subunit is a component of multisubunit complexes of high voltage-activated VDCCs composed of a calcium channel pore-forming α 1 (Ca V α 1 ) subunit and additional auxiliary β (Ca V β) and α 2 δ (Ca V α 2 δ) subunits which are necessary for the full physiological function of these channels. 4 Auxiliary subunits modulate biophysical properties of these calcium channels, generate a molecular signal for correct trafficking of this channel to plasma membrane, and stabilize the pore-forming α 1 subunit. 3, 4 Spontaneously hypertensive rats (SHR) represent a model of experimental hypertension characterized by increased calcium current density in vascular smooth muscle cells, 5 augmented activity of sympathetic nervous system (SNS), 6 and decreased baroreflex sensitivity. 7 The L-type VDCCs (L-VDCC, known as Ca V 1.2 channels) play an essential role in elevated calcium entry into vascular smooth muscle and in abnormal vascular tone of adult SHR. 8 The inhibition of L-VDCC by dihydropyridine calcium channel blocker (eg, nifedipine) induced greater decrease of blood pressure (BP) in SHR than in normotensive Wistar-Kyoto (WKY) rats. 9, 10 The N-type VDCCs (N-VDCC, known as Ca V 2.2 channels) play dominant role in the depolarization-evoked release of norepinephrine from sympathetic nerve terminals. 11 Selective blockade of N-VDCC by ω-conotoxin GVIA inhibited both excitatory junctional potentials and contractions of isolated arteries evoked by norepinephrine release induced by electrical field stimulation of perivascular nerves. 12 BP decrease and a marked increase of vascular conductance induced by ω-conotoxin GVIA were more pronounced in SHR than in WKY rats. 13 Moreover, ω-conotoxin GVIA almost totally abolished the sympathetic component of the baroreflex control of heart rate (HR) without affecting the vagal tone in SHR and WKY rats. 13 Gabapentinoid drug pregabalin decreased plasma membrane expression of both Ca V subunits (α 2 δ and α 1 ), inhibited calcium current through L-VDCC in isolated arterial myocytes, dilated pressurized cerebral arteries, and reduced their myogenic tone. 14 Bannister et al 15 reported that genetic hypertension in SHR is associated with an elevation in α 2 δ-1 expression that promotes surface trafficking of L-VDCCs in cerebral arterial myocytes. This leads to an increase in calcium current density and vasoconstriction. Indeed, the in vitro incubation of SHR cerebral arteries with pregabalin normalized L-VDCC surface expression, calcium current density, and smooth muscle contraction to the level of WKY rats. 15 In neurons, the increased expression of α 2 δ subunit resulted in improved synaptic targeting of VDCCs and enhanced release probability, which occurs independently of the trafficking effect. 16 Although acute gabapentin administration does not modify BP and HR of normotensive rats, 17, 18 it attenuates cardiovascular response to painful stimuli. 18 However, no detailed study of gabapentinoid drugs influence on BP regulation were performed in hypertensive rats. It remains an open question whether ligands of α 2 δ subunit also affect high voltage-activated VDCCs responsible for neurotransmitter release at sympathetic nerve terminals. The aim of the present study was (1) to evaluate the acute and chronic effects of gabapentin on BP and HR of conscious adult SHR and WKY rats and to compare acute gabapentin effects with those of nifedipine (L-VDCCs blocker) and ω-conotoxin GVIA (N-VDCCs blocker), (2) to study gabapentin effects on periarterial nerve stimulation (PNS) and phenylephrineinduced contraction of perfused mesenteric vascular bed isolated from SHR and WKY rats, (3) to test the role of SNS in gabapentin-induced BP and HR changes, and (4) to examine a possible influence of gabapentin on altered baroreflex control of HR in conscious SHR with established hypertension.
Methods
The authors declare that all supporting data are available within the article and in the online-only Data Supplement; detailed data are available from the corresponding author on reasonable request.
Animals
Male WKY rats and SHR aged 24 to 32 weeks were obtained from the breeding colony of the Institute of Physiology, Czech Academy of Sciences (Prague). Animals were housed under standard laboratory conditions (temperature, 23±1°C; 12-hour light/dark cycle; pelleted Altromin diet and tap water ad libitum). All procedures and experimental protocols were approved by the Ethical Committee of the Institute of Physiology at the Czech Academy of Sciences and were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Direct Measurements of BP and HR
Rats were instrumented with arterial catheter for direct BP measurement and venous catheter for drug application as described previously.
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BP and HR Measurement by Radiotelemetry
To measure hemodynamic parameters in freely moving rats, BP telemetry transmitters (model TA11-PAC40 or HD-S10; Data Sciences International, MN) were implanted as described previously.
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Sympathectomy
Particular groups of WKY rats and SHR were sympathectomized by daily intraperitoneal administration of guanethidine (30 mg/kg per day) for 2 weeks. 20 The efficacy of sympathectomy was verified by cardiovascular responses to ganglionic blocker pentolinium (5 mg/ kg) or catecholamine releasing agent tyramine (100 µg/kg).
Effects of Acute and Chronic Gabapentin Administration on BP and HR
We compared acute intravenous effects of gabapentin (100 mg/kg) with those of nifedipine (0.75 mg/kg) or ω-conotoxin GVIA (10 µg/ kg) on mean arterial pressure (MAP) and HR in partially restrained rats (kept in small transparent cages). Acute intravenous gabapentin effects were also determined in sympathectomized rats. Chronic gabapentin treatment (≈1200 mg/kg per day in 5% sucrose solution because of the taste issue of the drug) lasted 10 days. Cardiovascular response to acute and chronic oral administration of gabapentin was also studied in freely moving rats by radiotelemetry.
Baroreceptor Reflex Control of HR
Baroreceptor-HR reflex experiments were analyzed by a 5-parameter sigmoidal logistic function curve. 21 We also calculated the slopes of regression lines from either nitroprusside-induced MAP reduction followed by reflex tachycardia or phenylephrine-induced MAP elevation followed by reflex bradycardia.
Power Spectral Analysis
Power spectral analysis of systolic BP variability (SBPV) was used to evaluate the acute effects of gabapentin on particular frequency components of SBPV.
22,23
Plasma Levels of Catecholamines
Plasma levels of epinephrine and norepinephrine were measured by commercial enzyme immunoassay kit (2-CAT [A-N] Research ELISA, LDN, Germany).
Perfusion of the Isolated Mesenteric Vascular bed
Frequency-response curves to PNS and noncumulative dose-response curves to phenylephrine were studied in mesenteric vascular beds prepared for perfusion according to McGregor 24 with modifications reported by Kawasaki et al. 25 In Vitro Vascular Contraction Short-term (60 minutes) and long-term (24 hours) effects of gabapentin (1 mmol/L) on phenylephrine-induced or K + -induced contraction of femoral arteries dissected from SHR and WKY rats were studied using Mulvany-Halpern wire myographs.
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Statistical Analysis
All results are expressed as mean±SEM. Statistical analysis and sigmoidal logistic curve fitting were performed using SigmaPlot 13.0 (Systat Software, CA). Two-group comparisons were performed using unpaired or paired Student t test after the normal distribution of data were confirmed by Shapiro-Wilk test. Multiple-group comparisons were performed by 1-way or 2-way ANOVA followed by Bonferroni post hoc test as appropriate. P<0.05 was considered statistically significant.
Results
Acute Effects of Gabapentin on BP and HR in Partially Restrained Rats
Baseline values for MAP and HR in partially restrained conscious SHR (160±3 mm Hg; 366±10 bpm) were significantly higher than in WKY rats (103±3 mm Hg; 318±8 bpm; P strain <0.001 for both). BP and HR responses elicited by the dose-dependent intravenous administration of gabapentin (15-200 mg/kg) are shown in Figure S1 in the online-only Data Supplement. Maximal BP and HR effects were achieved at the dose of 100 mg/kg which was used in all subsequent experiments. Figure 1A and 1D show that gabapentin substantially lowered MAP and HR of SHR from baseline within 30 minutes after its acute injection (−20% and −12%, respectively; P treatment <0.001 for both), whereas its effect on MAP and HR in WKY rats was considerably smaller (−5% and −5%; P treatment <0.05 for both). To evaluate a possible contribution of L-VDCC and N-VDCC to gabapentin-induced hemodynamic changes, we have compared them with the acute effects of the inhibition of these subtypes of calcium channels by nifedipine or ω-conotoxin GVIA. Nifedipine reduced MAP in both strains (SHR, −23% and WKY rats, −12%; P treatment <0.001 for both; Figure 1B ) and this effect was greater in SHR than in WKY rats (P strain <0.001). Nifedipine-induced rapid MAP reduction was associated with HR acceleration (SHR, 14% and WKY rats, 16%; P treatment <0.05 for both; Figure 1E ) which was similar in both strains (P strain =0.664). MAP reduction induced by ω-conotoxin GVIA (SHR, −42% and WKY rats, −33%; P treatment <0.001 for both; Figure 1C ) was also greater in SHR than in WKY rats (P strain <0.001). This rapid MAP reduction was not accompanied by HR increase (SHR, −2% and WKY rats, −5%; P strain =0.575; Figure 1F ). Gabapentininduced reductions of MAP and HR lasted for at least 3 hours.
We also examined the additivity of acute intravenous gabapentin-and nifedipine-induced cardiovascular effects. Gabapentin pretreatment for 40 minutes did not significantly modify the immediate MAP response to nifedipine (SHR, −53±5 mm Hg and WKY rats, −24±6 mm Hg; P strain <0.01) as compared to nonpretreated rats (SHR, −63±4 mm Hg and WKY rats, −16±3 mm Hg; P pretreatment SHR =0.117 and P pretreatment WKY =0.172). However, pretreatment with gabapentin prevented the immediate nifedipine-induced HR acceleration in both strains (SHR, 14±18 bpm and WKY rats, 28±13 bpm; P strain =0.561) as compared to nonpretreated rats (SHR, 80±10 bpm and WKY rats, 81±9 bpm; P pretreatment <0.01 for both).
All 3 studied VDCC inhibitors (nifedipine, ω-conotoxin GVIA, and gabapentin) were able to reduce BP more in SHR than in WKY rats. Our data also indicate the additivity of gabapentin and nifedipine effects on MAP.
Acute and Chronic Effects of Gabapentin on BP and HR in Freely Moving Rats
Furthermore, we compared hemodynamic response to gabapentin in freely moving SHR and WKY rats using radiotelemetry ( Figure S2 ). Baseline MAP values were higher in SHR (144±5 and 103±3 mm Hg; P strain <0.001), whereas baseline HR values were lower in SHR than in WKY rats (291±4 and 309±5 bpm; P strain <0.01). Oral administration of gabapentin (100 mg/ kg) was followed by a substantial MAP reduction in freely moving animals within 60 to 90 minutes after gavage (SHR, −11% and WKY rats, −8%; P treatment <0.01 for both), but HR was not changed ( Figure S2 ). Gabapentin elicited a considerably smaller MAP decrease in freely moving than in restrained SHR (−11% and −20%; P<0.01). Gabapentin pretreatment did not modify MAP response to restraint stress in either strain, whereas it reduced stress-induced HR response in SHR only ( Figure S3 ). Despite the chronic administration of high gabapentin dose (≈1200 mg/kg per day in 5% sucrose solution because of the taste issue of the drug), we did not observe BP reduction in either rat strain during 10 days of treatment ( Figure S4 ). In contrast, chronic gabapentin treatment caused a mild elevation of BP and HR during last 2 to 3 nights which might be explained by chronic effects of sucrose on BP.
Gabapentin Effects on Contraction of Isolated Arteries
We studied the effects of phenylephrine and extracellular K + on force development in de-endothelized segments of femoral arteries from SHR and WKY rats ( Figure S5 ). Short-term exposure to gabapentin for 60 minutes moderately attenuated phenylephrine-induced contraction of SHR but not WKY rat arteries (reduced the potency, but it did not affect the efficacy of phenylephrine), but it had no effect on K + -induced contraction. Long-term exposure to gabapentin for 24 hours slightly reduced K + -induced contraction in SHR but not in WKY rat arteries.
Effects of Gabapentin on Vasoconstrictor Responses of the Isolated Mesenteric Bed
The mean basal perfusion pressure was higher in mesenteric vascular bed isolated from SHR (25.3±0.9 mm Hg) than from WKY rats (19.9±1.0 mm Hg; P strain <0.001). The efficacy of frequency-response curves (maximal response) to PNS was higher in SHR (142±15 mm Hg) than in WKY rats (85±19 mm Hg; P strain <0.05). The potency of frequency-response curves to PNS indicated by the negative logarithm of the half maximal effective concentration (pEC50) did not differ in both strains (SHR, 12.6±1.6 and WKY rats, 10.3±1.0; P strain =0.301). Acute gabapentin pretreatment for 40 minutes did not modify basal perfusion pressure (SHR, 28.5±2.4 mm Hg and WKY rats, 19.5±0.7 mm Hg; P strain <0.01). The efficacy (but not potency) of frequency-response curves to PNS was significantly reduced by acute gabapentin pretreatment in SHR (P treatment SHR <0.05; Figure 2A ). Relative changes of mean perfusion pressure elicited by PNS in acutely gabapentinpretreated rats were similar in both strains (SHR, −39% and WKY rats, −42%; P strain =0.284). Maximal pressure response to phenylephrine was higher in mesenteric vascular bed isolated from SHR (123±7 mm Hg) than from WKY rats (43±3 mm Hg; P strain <0.001). Acute gabapentin pretreatment did not affect noncumulative dose-response curves to phenylephrine in either rat strain ( Figure 2C and 2D) . Chronic administration of gabapentin for 10 days did not modify basal perfusion pressure (SHR, 25.7±1.6 mm Hg and WKY rats, 19.4±1.0 mm Hg; P strain <0.05) and caused similar changes on vasoconstrictor responses of the isolated mesenteric beds as acute gabapentin pretreatment (Figure 2A ). This is true for both PNS and phenylephrine effects in both rat strains. The only observed exception was a decrease of maximal pressure response to higher doses of phenylephrine in SHR after chronic gabapentin treatment (−20% and −30%; P treatment SHR <0.05 for both; Figure 2C ). Major effect of gabapentin on PNS but not on phenylephrine response suggest that gabapentin affects more norepinephrine release from sympathetic nerve terminals than directly vascular smooth muscle.
Influence of Sympathectomy on Gabapentin Cardiovascular Effects
To examine the role of SNS in the observed gabapentininduced MAP and HR effects, we compared acute intravenous gabapentin effects in nonsympathectomized and guanethidinesympathectomized (Sympx) rats (Figure 3) . Baseline values for MAP and HR of sympathectomized partially restrained conscious rats (SHR, 134±3 mm Hg and 317±7 bpm; WKY rats, 89±3 mm Hg and 275±9 bpm; P strain <0.01 for both) were significantly lower (P sympx <0.001 in both strains) than in nonsympathectomized rats (SHR, 184±3 mm Hg and 378±5 bpm; WKY rats, 118±4 mm Hg and 315±4 bpm; P strain <0.001 for both). The efficacy of sympathectomy was documented by major attenuation of MAP response to ganglionic blockade by pentolinium (SHR, −12% and WKY rats, −16%, respectively; P strain =0.72) compared with nonsympathectomized rats (SHR, −48% and WKY rats, −43%, respectively; P sympx <0.001 for both; Table S1 ). Successful sympathectomy was also confirmed by the lack of MAP and HR response to bolus injection of tyramine (Table S1 ) and drastic reduction of adrenergic innervation of femoral arteries in both strains ( Figure S6) . Figure 3A and 3B shows that the sympathectomy almost abolished MAP-lowering effect of acute intravenous gabapentin compared with nonsympathectomized animals of both strains (SHR, −2% and −22%; WKY rats, −1% and −12%; P sympx <0.001 for both). These results indicate that gabapentin lowers MAP through the attenuation of peripheral sympathetic vasoconstriction. However, there was no influence of sympathectomy on gabapentin-induced bradycardia in sympathectomized compared with nonsympathectomized SHR (−15% and −13%, respectively; P sympx =0.43), indicating different mechanisms responsible for MAP and HR changes elicited by gabapentin ( Figure 3C and 3D) . The assumed influence of gabapentin on SNS was further documented by the observation that gabapentin pretreatment attenuated pentolinium-induced MAP reduction compared with rats not pretreated with gabapentin (SHR, −22% and −48%, P treatment SHR <0.001; WKY rats, −34% and −43%, P treatment WKY =0.063). This effect was absent in sympathectomized rats (SHR, −17% and −12%, P treatment SHR =0.170; WKY rats, −13% and −16%, P treatment WKY =0.632). However, gabapentin pretreatment did not modify MAP and HR response to tyramine in either rat strain (Table S1 ). The absence of BP effect of gabapentin in sympathectonized animals supports the neural mechanism of its BP-lowering action.
Role of Plasma Catecholamines in Gabapentin Cardiovascular Effects
Basal levels of plasma epinephrine and norepinephrine are elevated in partially restrained SHR compared with WKY rats (Table) . Gabapentin administration decreased plasma levels of epinephrine and norepinephrine in SHR. Similar changes of plasma epinephrine levels were also elicited by gabapentin in WKY rats. Moreover, guanethidine-induced sympathectomy decreased plasma norepinephrine levels but increased epinephrine levels in both strains. In sympathectomized SHR-gabapentin decreased epinephrine but not norepinephrine levels, whereas gabapentin-induced changes of plasma catecholamines were not significant in sympathectomized WKY rats (Table) . These results indicate that the reduction of plasma epinephrine level may be the cause of observed gabapentin-induced bradycardia in SHR.
Gabapentin Effects on Baroreceptor-HR Reflex
To evaluate a possible contribution of L-VDCC and N-VDCC to gabapentin-induced changes of baroreceptor-HR reflex, we compared them with the effects of acute injection of nifedipine or ω-conotoxin GVIA in partially restrained conscious SHR and WKY rats. Baroreceptor-HR reflex experiments were analyzed by using a sigmoidal logistic function curve (Figure 4) . We also calculated slopes of regression lines from either nitroprusside-induced MAP reduction and reflex tachycardia or phenylephrine-induced MAP elevation and reflex bradycardia of baroreflex control (Table S2 ). Both arms of baroreceptor-HR reflex were diminished in nonpretreated SHR compared with WKY rats. Pretreatment with gabapentin or ω-conotoxin GVIA but not with nifedipine almost abolished the tachycardic response to sodium nitroprusside in both rat strains without a significant influence on the bradycardic response to phenylephrine ( Figure 4 ; Table S2 ).
Nitroprusside-induced tachycardia as a part of baroreflex HR control was attenuated by sympathectomy in both strains, whereas phenylephrine-induced bradycardia was not changed (Table S2 ). Gabapentin pretreatment did not modify either component of baroreceptor-HR reflex in sympathectomized SHR or WKY rats. These data confirmed the importance of SNS in gabapentin-induced effect on BP and baroreflex sensitivity control.
SBPV Evaluated by Power Spectral Analysis
We examined the frequency components of SBPV detected by power spectral analysis of beat-to-beat systolic BP in partially restrained conscious SHR and WKY rats before and after the acute intravenous administration of gabapentin, nifedipine, or ω-conotoxin GVIA ( Figure 5 ; Table S3 and E) , or ω-conotoxin GVIA (CTX; C and F) on baroreflex curves in partially restrained conscious spontaneously hypertensive rats SHR (A-C) and Wistar-Kyoto (WKY; D-F) rats. Scatter plot with bidirectional error bars represents relationship between heart rate (HR) and mean arterial pressure (MAP). Baroreflex curves were fitted with a 5-parameter sigmoidal logistic curve. The effects of either GBP or NIF or CTX (gray circles) are always compared with untreated controls (SHR, black circles; WKY, white circles). Values are mean±SEM. The thin cross in each scatter plot represents MAP and HR of corresponding group measured before baroreflex curves determination (control, n=8 rats per group; GBP, n=6-7 rats per group; NIF, n=6-7 rats per group; CTX, n=6 rats per group). See Table S2 for the detailed analysis of the slopes of regression lines from either nitroprusside-induced MAP reduction, reflex tachycardia (sympathetic component), or phenylephrineinduced MAP elevation, reflex bradycardia (vagal component) of baroreflex control.
high frequency [HF; 1-4 Hz]) domains were greater in SHR than in WKY rats (Table S3 ). Both LF domain power and LF/HF ratio, which are markers of sympathetic vascular activity, were reduced by pretreatment with gabapentin or ω-conotoxin GVIA in both rat strains, whereas nifedipine pretreatment did not change LF domain power ( Figure 5A and 5D). Gabapentin and ω-conotoxin GVIA abolished differences in LF/HF ratio between SHR and WKY rats, whereas nifedipine reduced this difference. Furthermore, sympathectomy lowered the power of LF domain and LF/HF ratio in both rat strains compared with nonsympathectomized animals ( Figure 5B and 5E). The effect of gabapentin on these parameters in sympathectomized rats was substantially smaller compared with rats with intact SNS (Table S4) . We also analyzed SBPV in freely moving rats with implanted telemetry transmitters ( Figure S2 ) which were subjected to 60 minutes of moderate restraint stress ( Figure S3 ). LF/HF ratio was not different between strains, whereas LF domain power was only 2× higher in nonstressed freely moving SHR compared with WKY rats (Figure 5C and 5F; Table S5 ). Both LF domain power and LF/HF ratio were increased by restraint stress (analyzed at 5 and 60 minutes) more in SHR than in WKY rats. Acute gabapentin pretreatment not only decreased basal LF domain power and LF/HF ratio in nonstressed rats but also abolished stress-induced increase of these markers of sympathetic vascular activity (Figure 5C and 5F; Table S5 ). Power spectral analysis of SBPV indicated that gabapentin lowered SNS contribution to BP maintenance and that the level of SNS activity was crucial for the magnitude of gabapentin-induced BP decrease.
Discussion
The main finding of the present study is that acute systemic administration of gabapentin (the ligand of α 2 δ subunit of VDCC) lowered BP more in conscious SHR than in WKY rats. Hypotensive effect of gabapentin was accompanied by a reduction of several indirect measures of SNS activity, including plasma norepinephrine level, depressor response to pentolinium, and power of LF component of SBPV.
Gabapentin pretreatment also attenuated pressor response to PNS of the isolated mesenteric vascular beds of SHR, but it did not modify direct pressor effects of phenylephrine. Moreover, gabapentin administration almost abolished the nitroprusside-induced tachycardia of baroreceptor-HR reflex. Indeed, the sympathectomy prevented MAP-lowering effect of gabapentin compared with nonsympathectomized animals. Nevertheless, chronic gabapentin treatment did not lower BP in SHR but still attenuated pressor response to PNS in isolated mesenteric vascular beds. These findings suggest that gabapentin administration lowered BP of conscious SHR mainly through the attenuation of sympathetic nerve transmission. Acute systemic administration of gabapentin lowered BP more in SHR than in WKY rats. To evaluate which type of VDCCs was affected by gabapentin, we compared gabapentin-induced hemodynamic changes with the effects of acute blockade of L-VDCCs by nifedipine or N-VDCCs by ω-conotoxin GVIA. These 2 types of calcium channels play an essential role in hypertension development in SHR. 5, 6, 13 In our experiments, both nifedipine and ω-conotoxin GVIA lowered BP markedly in SHR, but their effects on HR were completely different. Acute administration of nifedipine Figure 5 . The low frequency domain power (LF; A, B, and C) and the ratio of LF to high frequency powers (LF/HF ratio; D, E, and F) calculated by power spectral analysis of systolic blood pressure variability; in partially restrained spontaneously hypertensive rats (SHR) and Wistar-Kyoto (WKY) rats pretreated with gabapentin (GBP), nifedipine (NIF), or ω-conotoxin GVIA (CTX; A and D); in partially restrained nonsympathectomized (SHR and WKY rats) or guanethidine-sympathectomized rats (Sympx SHR and Sympx WKY rats) pretreated with saline or GBP (B and E); and in freely moving SHR and WKY rats pretreated with saline or GBP which were subsequently subjected to 60 min of moderate restraint stress (C and F). Data are expressed as mean±SEM. *P<0.05 vs the respective WKY rat group with the same treatment; †P<0.05 vs untreated nonsympathectomized control (ctrl) group of the same strain; ‡P<0.05 vs nonsympathectomized group with the same treatment; §P<0.05 vs nonstressed freely moving basal group of the same strain and treatment.
caused a pronounced BP reduction and marked HR increase. These results are in line with previous human studies showing that short-acting dihydropyridine calcium channel blockers (eg, nifedipine) exert clear-cut sympathoexcitatory effects, which are reflected by the marked increase of HR, plasma norepinephrine, and LF component of HR variability because of the sympathetic counterregulation of BP reduction. 26 However, acute administration of ω-conotoxin GVIA lowered BP without changing HR in conscious rats of both strains, which is in line with a previous study by Pruneau and Bélichard. 13 In vitro ω-conotoxin GVIA blocks the evoked norepinephrine release from sympathetic nerve terminals through the blockade of N-VDCCs. 11, 12 However, it does not directly affect VDCCs in smooth, skeletal, or cardiac muscle cells 27 and has no effects on vascular or cardiac contractility. 12, 13 We, therefore, studied gabapentin effects on norepinephrine release from sympathetic nerve terminals in mesenteric vascular beds subjected to PNS. Our data indicated that gabapentin pretreatment attenuated pressor response to PNS in SHR mesenteric vessels, whereas it had no effect on their pressor response to phenylephrine. In addition, we have observed 2 interesting effects of chronic gabapentin treatment which could be ascribed to direct vascular action of gabapentin. Pressor response to higher phenylephrine doses was attenuated in mesenteric vascular beds of SHR chronically treated with gabapentin, and K + -induced contraction was moderately reduced in isolated SHR femoral arteries exposed to gabapentin for 24 hours. Our data obtained in isolated conduit arteries are in line with the important role of calcium entry through L-VDCC in vascular contraction in SHR, 8, 20 as well as with upregulated α 2 δ functionality which contributes to the increased calcium currents in arterial myocytes of SHR. 15 Thus, gabapentin seems to act as both a weak L-VDCC blocker and an effective chronic inhibitor of α 2 δ surface expression in arterial myocytes. 14, 15 Hemodynamic response to acute gabapentin administration was enhanced in our restrained SHR compared with freely moving ones. These stress-related findings suggest that gabapentin may cause cardiovascular changes through the blockade of VDCCs in SNS. Indeed, sympathoexcitatory tachycardia following nifedipine administration was prevented by gabapentin pretreatment. The acute gabapentin administration attenuated cardiovascular response to painful stimuli 18 and also reversed the allodynia-associated BP increase in rats. 17 Recent meta-analysis of randomized clinical trials confirmed that gabapentin attenuated the increase of BP and HR following endotracheal intubation. 28 These cardiovascular changes are mediated by the increased circulating catecholamines because of SNS activation and enhanced sympathoadrenal response. 29 Thus, gabapentin causes acute cardiovascular changes through the attenuation of sympathoneural and sympathoadrenal activity.
To confirm the role of SNS in hemodynamic response to gabapentin, we compared gabapentin effects in nonsympathectomized and guanethidine-sympathectomized rats. Indeed, gabapentin did not lower BP in sympathectomized SHR. Gabapentin-induced reduction of HR in sympathectomized SHR could be explained by the fact that gabapentin decreased plasma epinephrine levels also in sympathectomized SHR. Gabapentinoid drugs reduced catecholamine release from adrenal chromaffin cells because of the less effective triggering of vesicle fusion 30 and limited catecholamine release owing to the inhibition of VDCCs and exocytosis in chromaffin cells. 31 Power spectral analysis is a useful tool for the evaluation of mechanisms involved in BP regulation. BP fluctuation elicited by sympathetic modulation of vascular tone occurs in the LF band of SBPV. LF power and LF/HF ratio of SBPV belong to markers of sympathetic vascular activity, 22 which can be used in either anesthetized or conscious rats. 32 These parameters were increased in our SHR compared with WKY rats; they were lowered by gabapentin and ω-conotoxin GVIA, as well as by sympathectomy. Moreover, sympathectomy prevented gabapentin effects on LF power and LF/HF ratio of SBPV. Increased LF power of SHR was also reported by Bertera et al, 33 and sympathectomy is known to decrease LF power in rats. 34, 35 Tseng et al 36 described that the majority of neurons in rostral ventrolateral medulla are involved in the generation of the LF rhythm of sympathetic nerve activity which is responsible for LF rhythm in BP.
Baroreceptor-HR reflex measurements provide important information concerning the effects of drugs on sympathetic and vagal components of HR control. 37 Baroreflex control is diminished in both experimental 7, 38 and human essential hypertension. 39 Our measurement of baroreflex sensitivity in conscious SHR and WKY rats confirms the findings of Struyker-Boudier et al, 38 who demonstrated lower baroreflex sensitivity in SHR with established hypertension compared with WKY rats. We also confirm that baroreflex of hypertensive animals has diminished sensitivity mainly because of the reduced maximum capacity of the cardiac vagal component, 7 which was not affected by any VDCCs blocker used in our study. However, gabapentin almost completely abolished the nitroprusside-induced tachycardia of baroreflex curves in both strains. This gabapentin effect was similar to that of N-VDCCs blocker ω-conotoxin GVIA shown in our experiments, as well as in those of Pruneau and Bélichard. 13 In contrast, the acute administration of L-VDCCs blocker nifedipine administration did not affect baroreflex curve. Thus, our study of baroreceptor-HR reflex also pointed to the SNS involvement in hemodynamic effects of gabapentin.
Our results indicate that gabapentin exerts its acute hemodynamic effects via the attenuation of sympathetic nerve transmission. These effects of gabapentin, as well as similarity of BP effects of gabapentin and ω-conotoxin GVIA, suggests that gabapentin probably affects N-type VDCCs which play a key role in sympathetic control of cardiovascular system.
Perspectives
Both SHR and patients with essential hypertension are characterized by sympathetic hyperactivity of central origin. Therapeutic effects of gabapentin in epilepsy or pain seem
